Sancilio Pharmaceuticals registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing. The company intends to list on the Nasdaq Global Market under the symbol SPCI.

The underwriters for the offering are UBS Investment Bank, Piper Jaffray, JMP Securities and FBR.

This is an integrated specialty pharmaceutical company focused on developing and, in the future, commercializing products based on its proprietary Advanced Lipid Technologies (ALT) platform. Sancilio intends to utilize its current manufacturing facility to manufacture the proprietary product candidates, if approved. ALT is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs).

Lipids are hydrophobic or amphipathic molecules and include fatty acids (such as omega-3 and omega-6 fatty acids), steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). The business model is to apply the ALT platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body.

In addition to the primary focus of developing its proprietary products using the ALT platform, Sancilio makes use of and license rights to its proprietary ALT platform and other technologies to third parties as part of the development and manufacture of lipophilic API-based and soft-gelatin products at its facilities.

The company intends to use the net proceeds from this offering to develop its pipeline, as well as for working capital and general corporate purposes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.